. Author manuscript; available in PMC: 2016 Dec 15.

Published in final edited form as: J Geriatr Oncol. 2016 Jul 25;7(6):422–429. doi: 10.1016/j.jgo.2016.07.002

Table 1.

ACCENT trials and number of elderly stage III patients per trial used for the Adjuvant! Online evaluation analyses.

Trial	Years	Treatment Arms	N
CALGB 89803(18)	1999–2001	FU/LV vs. FU/LV + IFL	141
INT-0089(19)	1990–1992	FU/LEV vs. FU/LV (HD or LD) vs. FU/LV/LEV	721
MOSAIC(3)	1998–2001	FU/LV vs. FOLFOX	178
N0147(15)	2004–2009	mFOLFOX6 vs. mFOLFOX6 + cetuximab	445
NCCTG-89-46-51(20)	1989–1991	FU/LV +/− LEV for 6 or 12 months	211
NSABP C07(6)	2000–2002	FU/LV vs. FOLFOX	291
NSABP C08(14)	2004–2006	mFOLFOX6 vs. mFOLFOX6 + bevacizumab	311
PETACC-3(21)	1999–2002	FU/LV (AIO or LVFU2) vs. FOLFIRI	152
SWOG 9415(22)	1995–1999	Bolus vs. infusional FU/LEV/LV	157
XELOXA(5)	2003–2004	FU/LV vs. XELOX	360
TOTAL ACCENT	1989–2009		2,967

Abbreviations: CALGB, Cancer and Leukemia Group B; FU, fluorouracil; LV, leucovorin; IFL, irinotecan; INT, Intergroup; LEV, levamisole; HD, high dose; LD, low dose; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; mFOLFOX6, modified FOLFOX 6 as infusional/bolus fluorouracil, leucovorin, and oxaliplatin; NSABP, National Surgical Adjuvant Breast and Bowel Project; AIO, folic acid, fluorouracil, and irinotecan; LVFU2, semi-monthly fluorouracil and leucovorin; FOLFIRI, fluorouracil, leucovorin, and irinotecan; SWOG, Southwest Oncology Group; XELOX, intravenous oxaliplatin plus oral capecitabine.